NinePointTwo Capital’s Cytokinetics CYTK Stock Holding History

NinePointTwo Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,140	Closed	-$232K	–	264
2023 Q2	$232K	Buy	+7,140	New	+$264K	0.09%	165

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

NinePointTwo Capital's CYTK Position: Q3 2023 in Review

NinePointTwo Capital sold out of Cytokinetics (CYTK) in Q3 2023, closing a stake of 7,140 shares — an estimated $232K sold.

NinePointTwo Capital first reported a position in CYTK in Q2 2023 and held it in 1 quarter. The position peaked at $232K in Q2 2023. 250 funds tracked by Wall St. Rank hold CYTK as of Q3 2023.

NinePointTwo Capital reported no remaining Cytokinetics position as of Q3 2023 after selling out during the quarter.
NinePointTwo Capital sold 7,140 Cytokinetics shares in Q3 2023, an estimated $232K.
NinePointTwo Capital first reported a position in Cytokinetics in Q2 2023 and held it in 1 quarter.
NinePointTwo Capital's Cytokinetics position peaked at $232K in Q2 2023.
250 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.